Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Cancer Immunotherapy | Correction

Correction to: CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy

Authors: Seyed Mohammad Miri, Elham Tafsiri, William Chi Shing Cho, Amir Ghaemi

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Excerpt

Following publication of the original article [1], we were notified the Department of Virology, Pasteur Institute of Iran should have been mentioned as the only affiliation for the first and last author. The revised affiliation is reflected in this correction article. …
Literature
1.
Metadata
Title
Correction to: CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy
Authors
Seyed Mohammad Miri
Elham Tafsiri
William Chi Shing Cho
Amir Ghaemi
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01609-w

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

miR-138-5p inhibits the malignant progression of prostate cancer by targeting FOXC1

Primary research

RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer

Review

Emerging role of long noncoding RNA-encoded micropeptides in cancer

Primary research

SRSF3 functions as an oncogene in colorectal cancer by regulating the expression of ArhGAP30

Review

MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma

Primary research

Suppressive effects of plumbagin on the growth of human bladder cancer cells via PI3K/AKT/mTOR signaling pathways and EMT
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits